Axplora partners with the world’s leading patient-centric pharmaceutical and biotechnology companies, delivering top quality active ingredients on time and at scale, to the highest industry standards. It was created by the merger of two companies sharing a track record of high quality products, reliability and a complementary set of differentiated technologies: PharmaZell Group (a manufacturer of generic active pharmaceutical ingredients (API) with the two brands PharmaZell and Farmabios) and Novasep (a development partner to innovator clients).
Axplora is dedicated to helping pharmaceutical companies make critical medicines better, faster, safely, reliably, and sustainably benefitting patients worldwide. Leveraging its combined expertise and manufacturing capabilities across nine industrial sites in Europe and India, and an R&D facility in the USA, Axplora offers CDMO solutions to innovators for their small molecule and biomolecular APIs, as well as products that address lifestyle-induced respiratory, inflammatory, and liver diseases. Headquartered in Raubling (near Munich, Germany), Axplora employs 2,400 people around the world.